194 related articles for article (PubMed ID: 26510149)
1. Therapeutic venesection at the Australian Red Cross Blood Service: impact of the High Ferritin Application on management of hereditary haemochromatosis.
Bentley P; Bell B; Olynyk J
Aust Fam Physician; 2015 Aug; 44(8):589-92. PubMed ID: 26510149
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum ferritin - what should GPs know?
Goot K; Hazeldine S; Bentley P; Olynyk J; Crawford D
Aust Fam Physician; 2012 Dec; 41(12):945-9. PubMed ID: 23210117
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of HFE-related haemochromatosis and secondary causes of hyperferritinaemia and their association with iron overload in 1059 French patients treated by venesection.
Le Gac G; Scotet V; Gourlaouen I; L'Hostis C; Merour MC; Karim Z; Deugnier Y; Bardou-Jacquet E; Lefebvre T; Assari S; Ferec C
Aliment Pharmacol Ther; 2022 Apr; 55(8):1016-1027. PubMed ID: 35122291
[TBL] [Abstract][Full Text] [Related]
4. Phlebotomy patterns in haemochromatosis patients and their contribution to the blood supply.
Walkden D; Badami K
N Z Med J; 2012 Jul; 125(1358):29-34. PubMed ID: 22864154
[TBL] [Abstract][Full Text] [Related]
5. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels.
van Dijk BA; Laarakkers CM; Klaver SM; Jacobs EM; van Tits LJ; Janssen MC; Swinkels DW
Br J Haematol; 2008 Sep; 142(6):979-85. PubMed ID: 18557745
[TBL] [Abstract][Full Text] [Related]
6. H63D homozygotes with hyperferritinaemia: Is this genotype, the primary cause of iron overload?
de Diego C; Opazo S; Murga MJ; Martínez-Castro P
Eur J Haematol; 2007 Jan; 78(1):66-71. PubMed ID: 17042772
[TBL] [Abstract][Full Text] [Related]
7. Genetic screening for HFE hemochromatosis in 6,020 Danish men: penetrance of C282Y, H63D, and S65C variants.
Pedersen P; Milman N
Ann Hematol; 2009 Aug; 88(8):775-84. PubMed ID: 19159930
[TBL] [Abstract][Full Text] [Related]
8. Hereditary hemochromatosis: missed diagnosis or misdiagnosis?
Cherfane CE; Hollenbeck RD; Go J; Brown KE
Am J Med; 2013 Nov; 126(11):1010-5. PubMed ID: 24054178
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and clinical manifestations of compound heterozygous genetic haemochromatosis (CHGH): a non-invasive approach to clinical management.
Ramakrishna R; Gupta S; Sarathy K; Bowen A
Intern Med J; 2013 Mar; 43(3):254-61. PubMed ID: 22957807
[TBL] [Abstract][Full Text] [Related]
10. Haemochromatosis: evaluating the effectiveness of a novel patient self-management approach to venesection as blood donation.
Mishra S; Sim D; Flanagan P
N Z Med J; 2017 Jun; 130(1457):26-33. PubMed ID: 28617785
[TBL] [Abstract][Full Text] [Related]
11. Haemochromatosis.
Adams PC; Barton JC
Lancet; 2007 Dec; 370(9602):1855-60. PubMed ID: 18061062
[TBL] [Abstract][Full Text] [Related]
12. [Molecular genetic diagnostics and screening of hereditary hemochromatosis].
Zlocha J; Kovács L; Pozgayová S; Kupcová V; Durínová S
Vnitr Lek; 2006 Jun; 52(6):602-8. PubMed ID: 16871764
[TBL] [Abstract][Full Text] [Related]
13. Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study.
Adams PC; Reboussin DM; Barton JC; Acton RT; Speechley M; Leiendecker-Foster C; Meenan R; Passmore L; McLaren CE; McLaren GD; Gordeuk V; Dawkins F; Eckfeldt JH
Int J Lab Hematol; 2008 Aug; 30(4):300-5. PubMed ID: 18665827
[TBL] [Abstract][Full Text] [Related]
14. Haemochromatosis in a kidney transplant recipient: a case report.
Zakrocka I; Baranowicz-Gąszczyk I; Załuska W
BMC Nephrol; 2021 May; 22(1):201. PubMed ID: 34051741
[TBL] [Abstract][Full Text] [Related]
15. Hemochromatosis and iron-overload screening in a racially diverse population.
Adams PC; Reboussin DM; Barton JC; McLaren CE; Eckfeldt JH; McLaren GD; Dawkins FW; Acton RT; Harris EL; Gordeuk VR; Leiendecker-Foster C; Speechley M; Snively BM; Holup JL; Thomson E; Sholinsky P;
N Engl J Med; 2005 Apr; 352(17):1769-78. PubMed ID: 15858186
[TBL] [Abstract][Full Text] [Related]
16. Correlation between genotype and phenotype in hereditary hemochromatosis: analysis of 61 cases.
Sham RL; Ou CY; Cappuccio J; Braggins C; Dunnigan K; Phatak PD
Blood Cells Mol Dis; 1997 Aug; 23(2):314-20. PubMed ID: 9410475
[TBL] [Abstract][Full Text] [Related]
17. Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women.
Roe MA; Spinks C; Heath AL; Harvey LJ; Foxall R; Wimperis J; Wolf C; Fairweather-Tait SJ
Br J Nutr; 2007 Mar; 97(3):544-9. PubMed ID: 17313717
[TBL] [Abstract][Full Text] [Related]
18. Correlates of hepcidin and NTBI according to HFE status in patients referred to a liver centre.
Ryan E; Ryan JD; Russell J; Coughlan B; Tjalsma H; Swinkels DW; Stewart S; Crowe JP
Acta Haematol; 2015; 133(2):155-61. PubMed ID: 25277871
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of genetic haemochromatosis.
Dooley JS
Best Pract Res Clin Haematol; 2002 Jun; 15(2):277-93. PubMed ID: 12401308
[TBL] [Abstract][Full Text] [Related]
20. Elevated MCP-1 serum levels are associated with the H63D mutation and not the C282Y mutation in hereditary hemochromatosis.
Lawless MW; White M; Mankan AK; O'Dwyer MJ; Norris S
Tissue Antigens; 2007 Oct; 70(4):294-300. PubMed ID: 17767550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
